Individualized treatment strategy for HbeAg negative:
First line PEG-IFN and week 12 stopping rule
The cost effectiveness of the management of HBeAg negative chronic Heaptitis B could be improved significantly by a shift toward a response guide first line therapy with PEF-IFN followed by a switch to NAs in patients meeting weeK-12 HBVDNA/HBsAg stopping rule.
Decisional algorithms based on HBsAg and HBVDNA kinetics will be added to AASLD, EASL, APASL guidelines
Stopping rules validated according to HBsAg level and on treatment decrease, genotype specific, will be applied to the PEG-IFN treatment, whatever the HBe status
HBsAg threshold, probably genotype specific, will be identified and will allow to end NAs treatment without risk of relapses.